- Home
- NXTC vs LIQT Comparison
NXTC vs LIQT Comparison
Compare NXTC & LIQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- LIQT
- Stock Information
- Founded
- NXTC 2015
- LIQT 2004
- Country
- NXTC United States
- LIQT Denmark
- Employees
- NXTC N/A
- LIQT N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- LIQT Industrial Machinery/Components
- Sector
- NXTC Health Care
- LIQT Technology
- Exchange
- NXTC Nasdaq
- LIQT Nasdaq
- Market Cap
- NXTC 13.9M
- LIQT 16.1M
- IPO Year
- NXTC 2019
- LIQT N/A
- Fundamental
- Price
- NXTC $0.45
- LIQT $1.55
- Analyst Decision
- NXTC Strong Buy
- LIQT Strong Buy
- Analyst Count
- NXTC 2
- LIQT 2
- Target Price
- NXTC $3.50
- LIQT $4.80
- AVG Volume (30 Days)
- NXTC 346.6K
- LIQT 32.4K
- Earning Date
- NXTC 07-31-2025
- LIQT 08-13-2025
- Dividend Yield
- NXTC N/A
- LIQT N/A
- EPS Growth
- NXTC N/A
- LIQT N/A
- EPS
- NXTC N/A
- LIQT N/A
- Revenue
- NXTC N/A
- LIQT $14,986,815.00
- Revenue This Year
- NXTC N/A
- LIQT $36.89
- Revenue Next Year
- NXTC N/A
- LIQT $16.33
- P/E Ratio
- NXTC N/A
- LIQT N/A
- Revenue Growth
- NXTC N/A
- LIQT N/A
- 52 Week Low
- NXTC $0.22
- LIQT $1.34
- 52 Week High
- NXTC $1.82
- LIQT $3.20
- Technical
- Relative Strength Index (RSI)
- NXTC 44.08
- LIQT 52.73
- Support Level
- NXTC $0.45
- LIQT $1.55
- Resistance Level
- NXTC $0.49
- LIQT $1.86
- Average True Range (ATR)
- NXTC 0.06
- LIQT 0.10
- MACD
- NXTC -0.01
- LIQT 0.01
- Stochastic Oscillator
- NXTC 0.74
- LIQT 36.59
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.